Correction: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial by Pandharipande, Pratik P et al.
After publication of our article [1], we noted typo-
graphical errors in our tables and in the labelling of 
Figure 3. Th  ere have been no changes to the results or 
their interpretation.
In Tables 1, 2 and 3 the number of dexmedetomidine 
patients without sepsis should read 21 instead of the 
published 20. Th   e numbers in the corresponding text are 
correct. Th   e corrected tables can be found overleaf.
In Figure 3, in the “Patients at risk” table below the 
Kaplan-Meier curve, the dexmedetomidine and lorazepam 
labels are incorrect. Th  e top row should be labeled 
lorazepam and the bottom row should be labeled 
dexmedetomidine. Th  e corrected ﬁ   gure can be found 
overleaf.
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© 2011 BioMed Central LtdTable 1. Baseline characteristics of patients with and without sepsis*
  Patients with sepsis  Patients without sepsis
Variable  DEX (n = 31)  LZ (n = 32)  DEX (n = 21)  LZ (n = 19)
Age  60 (46, 65)  58 (44, 66)  61 (50, 68)  60 (52, 67)
Males  58% 41% 57% 53%
APACHE II  30 (26, 34)  29 (24, 32)  27 (20, 31)  25 (20, 30)
SOFA score  10 (9,13)  9 (8, 12)  9 (8, 12)  8 (7, 9)
IQCODE at enrollment  3 (3, 3)  3 (3, 3)  3 (3, 3)  3 (3, 3)
Medical  ICU  77% 81% 62%    47%
Surgical  ICU  23% 19% 38% 53%
Pre-enrollment lorazepam (mg)  1.5 (0, 5)  0 (0, 4)  0 (0, 4)  0 (0, 2)
Enrollment RASS  -3 (-4, -2)  -4 (-4, -3)  -3 (-4, 0)  -3 (-4, -1)
SIRS criteria
  Temperature (Fahrenheit)   37.5 (37, 38.3)  38 (37.2, 38.6)  36.7 (35.8, 37.8)  37.2 (36.2, 38.3)
  White blood count (103/μL)  12.5 (6.6, 21.7)  12.5 (7.7, 18.8)  14.6 (8.9,17.9)  10 (7.5,14)
  Systolic BP (mm Hg)  88 (78, 100)  83 (79, 100)  92 (90, 100)  90 (80,110)
  Heart rate (per minute)  113 (100, 134)  119 (96, 130)  80 (65,123)  107 (99, 126)
  Respiratory rate  26 (20, 33)  33 (27, 39)  20 (15 ,24)  24 (20,28)
Organ dysfunction at enrollment
 PaO2/FiO2 ratio  128 (105, 209)  126 (94, 198)  127 (72, 211)  145 (81, 223)
  Creatinine (mg/dL)  1.7 (0.8, 2.9)  1.0 (0.8, 1.8)  1.2 (1.0, 1.7)  0.9 (0.8, 1.4)
  Vasopressors    32% 56% 19%  5%
  Bilirubin (mg/dL)  0.5 (0.4, 0.8)  0.9 (0.4, 1.8)  0.6 (0.5, 1.6)  0.6 (0.4, 1.1)
 Platelets  (103/μL)  176 (61, 304)  183 (107, 266)  186 (101,242)  145 (114, 242)
Median (interquartile range) unless otherwise noted
*Abbreviations: DEX, dexmedetomidine; LZ, lorazepam; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment; 
IQCODE, Informant Questionnaire on Cognitive Decline in the Elderly; ICU, intensive care unit; SIRS, Systemic Infl  ammatory Response Syndrome; BP, Blood pressure.
Table 2. Outcomes of patients with and without sepsis*
  Patients with sepsis  Patients without sepsis
       Adjusted    Adjusted
Outcome variable  DEX (n = 31)  LZ (n = 32)  P value**  DEX (n = 21)  LZ (n = 19)  P value**
Duration of Brain Organ Dysfunction
  Delirium/coma-free days**  6.1 (4.3)  2.9 (3.2)  0.005  6 (4.7)  5.5 (3.6)  0.97
 Delirium-free  days†  8.1 (3.1)  6.7(2.9)  0.06  8.1 (3.5)  7.9 (2.8)  0.80
 Coma-free  days§  9.4 (2.9)  5.9 (4.2)  <0.001  8.9 (4)  8.8 (2.6)  1
Other clinical outcomes
 MV-free  days‡  15.2 (10.6)  10.1 (10.3)  0.03  12.8 (11.5)  17.2 (10)  0.15
  ICU days  13.4 (15.1)  12.2 (9.8)  0.81  14.9 (16.5)  10.4 (8.9)  0.28
  28-day  mortality  16% 41% 0.03 19%  5%  0.21
Mean (standard deviation) unless otherwise noted
Abbreviations: DEX, dexmedetomidine; LZ, lorazepam; ICU, intensive care unit; MV, mechanical ventilation
*Adjusted P value obtained from the bootstrap multiple linear regression that calculated a diff  erence in mean for each outcome between the two treatment groups, 
adjusting for age, severity of illness, use of drotrecogin alfa (activated) within 48 hours of enrollment, sepsis, treatment group, and a treatment group by sepsis 
interaction.
**Indicates the number of days alive without delirium or coma from study day 1 to 12.
†Indicates the number of days alive without delirium from study day 1 to 12.
§Indicates the number of days alive without coma from study day 1 to 12.
‡Indicates the number of days alive breathing without assistance of the ventilator from study day 1 to 28.
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Page 2 of 3Table 3. Hemodynamic parameters in patients with and without sepsis*
  Patients with sepsis  Patients without sepsis
Hemodynamic variable**  DEX (n = 31)  LZ (n = 32)  P value  DEX (n = 21)  LZ (n = 19)  P value
Number of days on vasoactive drugs  1 (1)  2 (2)  0.08  1.5 (2.2)  0.3 (0.9)  0.08
Average daily number of vasoactive drugs  1.1 (0.2)  1.6 (0.5)   0.004  1.6 (0.9)  1 (0)  0.2
Ever vasoactive drugs increased  26%  47%  0.08  33%  16%  0.2
Sinus bradycardia (< 60 beats/min)  13%  6%  0.4  24%  0%  0.02
Sinus tachycardia (> 100 beats/min)  81%  84%  0.7  52%  53%  1
Mean (standard deviation) unless otherwise noted
*Abbreviations: DEX, dexmedetomidine; LZ, lorazepam
** Measured during 120-hour study drug protocol, except for sinus bradycardia & sinus tachycardia, which are measured during entire study.
Figure 3. Kaplan-Meier curve showing probability of survival during the fi  rst 28 days according to treatment group, among patients with 
sepsis. Dexmedetomidine decreased the probability of dying within 28 days by 70%; this benefi  cial eff  ect was not seen in patients who were not 
septic (P value for interaction = 0.11 implying an interaction between sepsis and the treatment groups).
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